BRCA1 and cancer: A meta‐analysis of studies assessing this risk suggested only a 79% reduction in risk of an “ovarian” type cancer after RRBSO in BRCA1/2 PV carriers15 (hazard ratio = 0.21; 95% CI = 0.12‐0.39).